Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial.
Saved in:
| Title: | Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial. |
|---|---|
| Authors: | Hu J; Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, MN, USA., Babiker AG; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Reilly CS; Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, MN, USA., Baker JV; Division of Infectious Diseases and International Medicine, University of Minnesota, MN, USA.; Division of Infectious Diseases, Hennepin Healthcare, MN, USA., Siegel LK; Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, MN, USA. |
| Source: | Contemporary clinical trials communications [Contemp Clin Trials Commun] 2025 Dec 24; Vol. 49, pp. 101592. Date of Electronic Publication: 2025 Dec 24 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101671157 Publication Model: eCollection Cited Medium: Internet ISSN: 2451-8654 (Electronic) Linking ISSN: 24518654 NLM ISO Abbreviation: Contemp Clin Trials Commun Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
